New Lung Cancer Therapies Are In Development
Main Category: Lung CancerArticle Date: 14 Aug 2005 - 11:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
D Neil Watkins, MBBS, PhD, FRACP, assistant professor of oncology at Johns Hopkins University, can address new therapies directed against specific cellular pathways in lung cancer that are being developed with the hope of controlling the disease:
"These treatments are unlike conventional chemotherapy and do not usually damage normal cells. They include tyrosine kinase inhibitors, like Iressa and angiogenesis inhibitors, as well as other novel therapies."
Watkins received a 2005 Kimmel Grant for his work in the area of aberrant Hedgehog signaling in cancer.
ProfNet
Ste 200, 888 Veterans Highway
Hauppauge, NY 11788
USA
http://www.profnet.com
Visit our lung cancer section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/29104.php>
APA
http://www.medicalnewstoday.com/releases/29104.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




